COVID-19: potential cardiovascular issues in pediatric patients

Deborah Bertoncelli1, Marta Guidarini2, Anna Della Greca2, Chiara Ratti2, Francesca Falconella2, Brunella Iovane1, Mauro Luigi Dutto1, Carlo Caffarelli4, Bertrand Tchana1

1Pediatric Cardiology Unit, Parma General and University Hospital; 2School of Specialization in Pediatrics, University of Parma; 3General and Emergency Pediatrics Unit, Parma General and University Hospital; 4Department of Medicine and Surgery, University of Parma

Summary. The novel severe acute respiratory syndrome coronavirus 2 (SARS-COV 2) has rapidly spread worldwide with increasing hospitalization and mortality rate. Ongoing studies and accumulated data are detailing the features and the effects of the new coronavirus disease 19 (COVID 19) in the adult population, and cardiovascular involvement is emerging as the most significant and life-threatening complication, with an increased risk of morbidity and mortality in patients with underlying cardiovascular disease. At present, though the limited data on the effects of COVID 19 in pediatric patients, children seem to count for a little proportion of SARS-COV 2 infection, and present with less severe disease and effects. However infants and toddlers are at risk of developing critical course. The disease has a range of clinical presentations in children, for which the potential need for further investigation of myocardial injury and cardiovascular issues should be kept in mind to avoid misdiagnosing severe clinical entities. Overlapping with Kawasaki disease is a concern, particularly the incomplete and atypical form. We aim to summarize the initial considerations and potential cardiovascular implications of COVID-19 for children and patients with congenital heart disease. (www.actabiomedica.it)

Key words: COVID - 19, Children, Cardiovascular, Myocarditis, Kawasaki disease, Congenital heart diseases.

Introduction

Coronavirus disease 19 (COVID-19) is a severe acute respiratory syndrome for which the etiologic agent is the novel beta coronavirus SARS-CoV-2, first described in December 2019 in China in a cluster of patients presenting with pneumonia. In the past few months, the disease has spread worldwide and become a pandemic. Since the outbreak began, the virus has raised concerns among medical professionals worldwide because of the increasing rates of patient hospitalization and mortality. The main presenting clinical feature of the disease is pneumonia, ranging from asymptomatic or mildly symptomatic to severe acute respiratory distress syndrome, but cardiovascular involvement is emerging as one of the most significant and life-threatening complications of SARS-CoV-2 infection (1, 2). In addition, patients with underlying cardiovascular diseases (CVDs) may be subject to an increased risk of death (1,2,3). At present data are limited regarding the incidence and effects of COVID-19 in pediatric patients, but it seems that children present with less severe effects and disease. We aim to summarize the initial considerations and potential cardiovascular implications of COVID-19 for children and patients with congenital heart disease.

COVID-19 and Cardiovascular Injuries

Viral infection has been widely described as one of the most common infectious causes of myo-
carditis. Some reports suggest that SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV) share similar pathogenicity with SARS-CoV-2 (1), and since the previous coronavirus epidemics (SARS-CoV and MERS-CoV), known cases of myocarditis have been caused by these viruses (4-6). Furthermore, patients with underlying heart disease (both congenital or acquired) seem to have increased morbidity and mortality related to viral infections (7).

The pathogenesis of cardiac involvement associated with SARS-CoV-2 may reflect a process of replication and dissemination of the virus through the blood and/or the lymphatic system from the respiratory tract. SARS-CoV-2 may lead to cardiac injury via several hypothetical mechanisms:

- **The SARS-CoV-2 virus uses ACE2 as a receptor for entry into the cell; this enzyme is widely expressed in the lungs but also in the heart and blood vessels. It is unclear at this time, however, whether the SARS-CoV-2 binding alters ACE2 expression or causes dysregulation of the RAAS (renin-angiotensin-aldosterone system) pathway (8-11).**

- **Viral invasion may lead to an unbalanced response by type 1 and type 2 T helper cells, triggering an exaggerated inflammatory and immune response and a cytokine storm. The mechanism by which cytokines damage the myocardium is still unknown (12-17).**

- **The acute lung injury caused by the virus leads to acute respiratory damage and subsequent severe hypoxia, which may result in oxidative stress, endothelial shedding, microvascular damage, and myocardial injury due to increased myocardial oxygen demand (14, 18, 19).**

- **Direct viral toxicity to cardiomyocytes has been shown in other viral infections, such as Coxsackie virus or influenza-induced myocarditis, but in the setting of SARS-CoV-2 infection, though cases of myocarditis have been described (20-23), of cardiomyocytes viral invasion and direct damage have not yet been proven in pathology studies.**

SARS-CoV-2 infection facilitates the induction of endotheliitis as a direct consequence of viral involvement and of the host’s inflammatory response. Endothelial dysfunction is the main determinant of microvascular dysfunction because it shifts the vascular equilibrium toward more vasoconstriction, inflammation with associated tissue edema, and a procoagulant state, contributing to vessel thrombosis and subsequent organ ischemia (18, 19, 24).

Studies have shown that a significant percentage of patients affected with COVID-19 displayed evidence of myocardial injury (2, 3, 7, 13, 14, 17, 18). SARS-CoV-2 cardiac involvement mainly manifested as an increase in the levels of biomarkers of myocardial injury: high-sensitivity cardiac troponin I, N-terminal pro B-type natriuretic peptide, and CK-MB (1, 2, 7, 24, 25, 26). Patients with COVID-19 can present with chest pain, dyspnea, palpitations, dysrhythmia, and acute left ventricular dysfunction (1, 2, 18, 21, 28). Dysrhythmias may occur in the setting of viral illness due to hypoxia, inflammatory stress, and abnormal metabolism, but no specific ECG changes have been described in patients with SARS-CoV2 infection.

Myocardial injury may be drug-related. Although currently no specific effective therapies for COVID-19 exist, various pharmacologic agents are under active investigation, mainly antivirals (remdesivir, lopinavir/ritonavir, Favilavir), antimalarials (chloroquine, hydroxychloroquine), corticosteroids, monoclonal antibodies and antibiotics (azithromycin) (29-33). Many antiviral drugs can cause cardiac insufficiency, arrhythmia, or other cardiovascular disorders (1, 2, 17, 34, 35). Antimalarials and some antibiotics can cause QT interval prolongation and malignant arrhythmias (35, 36).

**Pediatric Patients**

Children do not seem to count for a large proportion of COVID-19 disease infections. Numbers gathered from different studies suggest a great deal of variation in incidence, 2% in the largest series from China, 1.2% in the pediatric cohort from Italy, 4.8% in Korea, and 1.7% in the United States (37, 38, 39, 40). It is possible that protective measures, especially social distancing from children and community closure, have impacted the incidence in pediatric patients. Only limited data detail the effects of COVID-19 on the pediatric population. Preliminary evidence suggests children are just as likely as adults to become infected with SARS-CoV-2 but are less likely to be sympto-
matic or develop severe symptoms. In the largest series published to date, 94.1% of the children were either asymptomatic or had mild to moderate disease (37, 41-44). Information about pediatric patients requiring intensive care is scarce. The largest pediatric series showed 5.2% of children with respiratory distress or hypoxia and 0.6% who progressed to acute respiratory distress syndrome or multiple organ dysfunction (37). Children under 5 years of age are at risk of developing severe disease, with infants presenting the highest risk (37, 42, 45, 46). Laboratory findings do not show a tendency toward immune dysregulation and blood count and pro-inflammatory markers may be normal, but altered liver function test results are common, as are D-dimers, especially in severe cases (38, 43, 44, 46).

Children with SARS-CoV-2 may present with flu-like features, fever, cough, and shortness of breath, as the most frequent symptoms (38, 42, 43, 47). Chest pain may be present in some cases, while others may show vomiting, abdominal pain, and diarrhea as the only symptoms (48). Infants and children with severe forms may present looking very ill, with cold extremities, weak peripheral pulses, and hepatomegaly (45, 46, 48). Tachycardia is seen as a result of multiple, simultaneous causes (fever, dyspnea, pain, anxiety, etc.) and is usually sinus tachycardia without any other significant signs on an ECG (48).

**Myocardial injury**

Acute myocardial injury is rare in children and adolescents. It is usually associated with either an acute inflammatory condition of the myocardium or the coronary arteries, or an anomalous origin in the left coronary artery.

Myocardial injury may derive from myocarditis, an inflammatory disease of the myocardium, or pericarditis, irritation or inflammation of the pericardial layers, with viral infection as the most commonly identified cause (Epstein-Barr virus, adenovirus, parvovirus B19, Coxsackievirus, influenza virus, enterovirus, and echovirus) (49-51). Children with SARS-CoV-2 may present with another viral agent coinfection (48). The clinical manifestations of myocarditis and pericarditis can range from mild nonspecific symptoms to chest pain to cardiogenic shock. Myocarditis in children may present with flu-like symptoms, shortness of breath, tachycardia, dyspnea, nausea, and decreased appetite, or poor feeding and tachypnea in infants (50, 51). In the fulminant form, the children are critically ill with cold extremities, weak peripheral pulses, a gallop rhythm, and hepatomegaly more commonly than rales and edema. Pericarditis, most common in adolescents, classically presents with chest pain exacerbated when supine, when coughing, or with inspiration and relieved by the sitting position (50, 51). Elevated cardiac biomarkers such as creatine kinase muscle-brain isoenzyme, troponin I, and troponin T (reported to have specificity of 86% and sensitivity of 71% in children) (51) and ECG anomalies (ST segment and T wave changes, QRS complex voltage) confirm the diagnosis of cardiac injury. Troponin I and T levels are more frequently elevated in acute myocarditis than are creatine kinase muscle-brain levels (50, 51). However, normal biomarker levels do not completely exclude myocarditis.

**COVID – 19 and Kawasaki disease**

COVID-19 may sometimes present with the clinical features of vasculitis, mimicking characteristics of Kawasaki disease, an acute febrile illness with cardiac involvement and a predilection for the coronary arteries, for which we can distinguish a typical, atypical and an incomplete form. In the typical form, Kawasaki disease is characterized by enanthem (mucous membrane rash), bulbar conjunctivitis, rash, lymphadenopathy, and extremity changes (52, 53). The incomplete form is diagnosed when the patient presents with typical fever, two or three of the principal clinical features, and suggestive laboratory findings such as elevated erythrocyte sedimentation rate, elevated C-reactive protein, hypoalbuminemia, anemia, elevated alanine aminotransferase, thrombocytosis, or leukocytosis (52, 53). Atypical form is characterized by typical fever and clinical features different from the main signs and symptoms of Kawasaki disease (pneumonia, acute abdomen, central nervous system involvement, nephritis, myositis, etc…) (52, 53). Although decades of investigation, and some evidence suggesting for an infectious trigger, etiology of Kawasaki disease remain unknown. Association of Kawasaki disease with viral respiratory infections have been described in several studies, including human coronavirus (54-57). Initial hypothesis of Dr Tomisaku Kawasaki was that a coro-
navirus was the etiologic cause of the mucocutaneous lymph node syndrome he was describing. Several clinical signs of Kawasaki disease providing important diagnostic clues have not been included in the diagnostic criteria, myocarditis, sterile pyuria, peripheral arthritis, and may also present with COVID-19 confounding furthermore the diagnosis. The cytokine storm present in a phase of SARS-COV 2 disease recall the role of inflammatory biomarkers in Kawasaki disease, particularly interleukine 6. In some cases, COVID-19 presentation may raise doubts, mainly related to incomplete or atypical Kawasaki disease, and differentiating the entities may be challenging but fundamental because of the potential serious cardiac sequelae.

Pre-existing cardiovascular diseases and congenital heart diseases

We learn from the adult cohort that patients with preexisting cardiovascular diseases have increased morbidity and mortality. According to a morbidity/mortality report by the Centers for Disease Control of the United States, among the pediatric cases with information on underlying conditions, the most common underlying condition after chronic lung disease was cardiovascular disease (58, 59). Up to now, no studies detail the risk of individual cardiovascular complications in patients with underlying cardiovascular disease who are infected with SARS-CoV-2, neither have any studies included patients with congenital heart disease. Standing on what is known some patients with congenital heart disease are at high risk, depending on the complexity of the lesion and their clinical and surgical status. Syndromic patients, especially those with reduced immunity, including heterotaxy syndrome, Down syndrome, DiGeorge syndrome, and asplenia, may be at even higher risk (7, 60). Children with congenital heart disease who may be at higher risk for serious illness from SARS-COV-2 include:

- Patients with single heart physiology: hypoplastic left heart syndrome, tricuspid atresia, pulmonary atresia, unbalanced atrioventricular canal, Glenn anastomosis, Fontan procedure
- Patients with surgical aorto-pulmonary connection, modified Blalock-taussig shunt, Waterson anastomosis, Potts anastomosis, pulmonary artery banding
- Patients with pulmonary hypertension
- Patients who are due to have surgery in the near future, large ventricular septal defect, atrioventricular septal defect, tetralogy of Fallot, total anomalous pulmonary venous return.

Any child with a cardiopathy requiring medication for heart failure, may experience a worsening of their clinical status because of the hemodynamic impact of the lung involvement and/or myocardial injury of SARS-CoV-2 infection. Children who have had previous heart surgery without sequelae and are not taking any heart medications may follow basic preventive indications.

**Arrhythmias and drug related issues**

COVID-19-related issues such as fever, electrolyte disturbance, and current treatment may have a pro-arrhythmic effect, making it challenging to manage the illness in children with inherited (long QT syndrome, Brugada syndrome, short QT syndrome and catecholaminergic polymorphic ventricular tachycardia) or acquired arrhythmias, sometimes associated with repaired or un repaired congenital structural heat lesions. Active studies are evaluating different agents to determine the best treatment, most of which may have serious undesired cardiovascular effects (2, 7, 34-36). Very few of these studies involve children, so data will have to be extrapolated from adult studies. Actual ongoing trials include (see Table 1)
- antivirals, especially lopinavir, ritonavir, and ribavirin;
- antimalarials, namely chloroquine and hydroxychloroquine;

| Medications                        | Cardiovascular effects                                      |
|-----------------------------------|-------------------------------------------------------------|
| Antivirals                         | Direct myocardial toxicity; Prolonged QTc, AV blocks, Torsades de pointes, Interaction with antiarrhythmics |
| Chloroquine and Hydroxychloroquine| Direct myocardial toxicity; Worsen cardiomyopathy; Bundle branch block; AV block; Ventricular arrhythmias; Torsades de pointes; Prolonged QTc |
| Azithromycin                       | Dysrhythmias; Prolonged QTc; Torsades de pointes             |
| Corticosteroids                    | Fluid retention; Hypertension, Electrolyte changes           |
| Tocilizumab                        | Hypertension                                                 |

Table 1. COVID 19 present medications and cardiovascular system
- azithromycin;
- corticosteroids, particularly methylprednisolone;
- biologics with tocilizumab.

ACE inhibitors and angiotensin receptor blockers (ARBs) are commonly used in various settings in pediatric cardiology. Some study authors stated that their use may have affected the course of COVID-19 (1); they suggested that ACE inhibitors (ACEis) and angiotensin receptor blockers (ARBs) may upregulate ACE2, thereby increasing susceptibility to the virus. Other studies, in contrast, show that ACEis/ARBs may potentiate the lung-protective function of ACE2, which is an angiotensin II inhibitor (61, 62). It remains controversial whether patients with COVID-19 under treatment with an ACE inhibitor or angiotensin-receptor blocker should switch to another drug, and further evidences are required. As such, the Heart Failure Society of America, American College of Cardiology, American Heart Association, and European Society of Cardiology released a statement recommending continuation of renin-angiotensin-aldosterone system inhibitors for patients currently taking them for “indications for which these agents are known to be beneficial”.

Conclusion

Cardiovascular issues are emerging as one of the most significant and life-threatening complications of SARS-CoV-2 infection in adult patients. Though pediatric critically ill COVID-19 patients remain rare, the disease has a range of clinical presentations in children, for which the potential need for further investigation of myocardial injury and cardiovascular issues should be kept in mind to avoid misdiagnosing severe clinical entities. Data are lacking for COVID-19 in some pediatric subpopulations, including in patients with underlying conditions, but some reports indicate that these populations are at increased risk of morbidity and mortality. Children with preexisting complex cardiovascular conditions may be at higher risk. If they require careful monitoring and follow-up in case of infection, extensive preventive measures must be taken with these patients. Frequent handwashing, social distancing measures, proper and appropriate use of masks and other personal protective equipment, and the use of technology should be prominent in their management to minimize the risk of nosocomial infections.

Conflict of interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

1. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260.
2. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic [published online ahead of print, 2020 Mar 18]. J Am Coll Cardiol. 2020;
3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published online ahead of print, 2020 Mar 3] [published correction appears in Intensive Care Med. 2020 Apr 6]. Intensive Care Med. 2020;
4. Yu CM, Wong RS, Wu EB, Kong SL, Wong J, Yip GW, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006 Feb;82(964):140-4.
5. Rao S, Sasser W, Diaz F, Sharma N, Alten J. Coronavirus Associated Fulminant Myocarditis Successfully Treated with Intravenous Immunoglobulin and Extracorporeal Membrane Oxygenation. Chest. 2014 Oct;146(4):336A.
6. Alhogbani, T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann. Saudi Med. 36, 78–80(2016).
7. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease [published online ahead of print, 2020 Mar 28]. Int J Cardiol. 2020
8. Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614–14621
9. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618–625
10. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7): e00127-20
11. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590
12. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103

13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;]. Lancet. 2020;395(10223):497–506.

14. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;]. Lancet Respir Med. 2020;8(4):420–422.

15. Zhu H, Rhee JW, Cheng P, et al. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep. 2020;22(5):32.

16. Yang C, Jin Z. An Acute Respiratory Infection Runs into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases [published online ahead of print, 2020 Mar 25;]. JAMA Cardiol. 2020;10.

17. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020

18. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published online ahead of print, 2020 Feb 24] [published correction appears in Lancet Respir Med. 2020 Apr;8(4):e26]. Lancet Respir Med. 2020;

19. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28;]. N Engl J Med. 2020;

20. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights [published online ahead of print, 2020 Apr 10;]. Infection

21. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Mar 27;]. JAMA Cardiol. 2020;

22. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis [published online ahead of print, 2020 Mar 5;]. Herz. 2020.

23. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin [published online ahead of print, 2020 Mar 16;]. Eur Heart J. 2020

24. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endothelitis in COVID-19 [published online ahead of print, 2020 Apr 20;]. Lancet. 2020.

25. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China [published online ahead of print, 2020 Mar 25;]. JAMA Cardiol. 2020

26. Zhou B, She J, Wang Y, Ma X. The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease [published online ahead of print, 2020 Mar 21;]. J Infect. 2020

27. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis [published online ahead of print, 2020 Mar 10;]. Prog Cardiovasc Dis. 2020

28. Vetter P, Vu DL, L’Huillier AG, Schibler M, Kaiser L, Jacquieroz F. Clinical features of covid-19. BMJ. 2020

29. World Health Organization. WHO interim guidance on clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. www.who.org

30. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed 2019 novel coronavirus (2019-nCoV) infection. www.cdc.gov

31. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477

32. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status [published online ahead of print, 2020 Apr 19;]. Infect Genet Evol. 2020;83

33. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60

34. Wu CI, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes [published online ahead of print, 2020 Mar 31;]. Heart Rhythm. 2020; S1547-5271(20)30285-X

35. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19 [published online ahead of print, 2020 Apr 18;]. Ann J Emerg Med. 2020

36. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19 [published online ahead of print, 2020 Apr 9;]. J Cardiovasc Electrophysiol. 2020

37. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020

38. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24;]. JAMA.

39. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy [published online ahead of print, 2020 Mar 17;]. JAMA. 2020

40. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663–1665

41. Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention. Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35(10):e112
COVID - 19: potential cardiovascular issues in pediatric patients

42. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China [published online ahead of print, 2020 Feb 14]. JAMA. 2020;323(13):1313–1314

43. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr Infect Dis J. 2020;39(5):355–368

44. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus [published online ahead of print, 2020 Feb 5]. World J Pediatr. 2020

45. Ong JSM, Tosoni A, Kim Y, Kissoon N, Murthy S. Coronavirus Disease 2019 in Critically Ill Children: A Narrative Review of the Literature [published online ahead of print, 2020 Apr 7]. Pediatr Crit Care Med. 2020

46. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr. 2020;63(4):125–132. doi:10.3345/cep.2020.00535

47. Morand A, Fabre A, Minodier P, et al. COVID-19 virus and children: What do we know? Arch Pediatr. 2020

48. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020;55(5):1169–1174

49. Cadoria AL, Pankanweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648d

50. Dasgupta S, Iannucci G, Mao C, Clabby M, Oster ME. Myocarditis in the pediatric population: A review. Congenit Heart Dis. 2019;14(5):868–877

51. Tunuguntla H, Jeewa A, Denfield SW. Acute Myocarditis and Pericarditis in Children. Pediatr Rev. 2019;40(1):14–25

52. Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association [published correction appears in Circulation. 2019 Jul 30;140(5):e181–e184]. Circulation. 2017;135(17):e927–e999

53. Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr. 2018;44(1):102

54. Holm JM, Hansen PK, Oxhøj H. Kawasaki disease associated with parvovirus B19 infection. Eur J Pediatr. 1995;154(8):633–634

55. Jordan-Villegas A, Chang ML, Ramilo O, Mejias A. Concomitant respiratory viral infections in children with Kawasaki disease. Pediatr Infect Dis J. 2010;29(8):770–772

56. Kim JH, Yu JJ, Lee J, et al. Detection rate and clinical impact of respiratory viruses in children with Kawasaki disease. Korean J Pediatr. 2012;55(12):470–473

57. Turner JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics. 2015;136(3):e609–e614

58. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422–426

59. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–386

60. Covid-19 and patients with congenital heart disease. Indications and suggestions from the Italian Society of Pediatric Cardiology and Congenital Heart Diseases. By the Board of the Italian Society of Pediatric Cardiology and Congenital Heart Diseases www.sicped.it

61. Imai Y, Kubo K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116.

62. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics [published online ahead of print, 2020 Mar 4]. Drug Dev Res. 2020

Received: 28 April 2020
Accepted: 30 April 2020
Correspondence:
Bertrand Tchana
Pediatric Cardiology Unit, Parma General and University Hospital
Via A. Gramsci 14, 43126 Parma, Italy
Fax: +39 0521 702208
Tel: +39 0521 703313
E-mail: btchana@ao.pr.it